Replies to post #229719 on Amarin Corp Plc (AMRN)

[couldbebetter]

Amazing that Goldman Sachs had a BO target of $85 on MDCO
before the (what may be an offer from NVS of $9.7 billion)
or...you guessed it! $85 per share. Right on target.

Note that the price of MDCO spiked to over $70 when Bloomberg
reported that NVS was in talks with NVS. (Someone needed the
price a bit higher before the actual BO price was announced.)

Will a similar scenario play out with AMRN assuming JT decides
the right offer is in place?

Just for comparison the $9.7 billion that MDCO may be paid would
equate to $23.50 for AMRN...and for company with no FDA approved
drug and zero sales.

[ferretmoney]

JL, you are right - it is complicated. This website was so slow last night that it was impossible to edit and try to make it more readable. Let me just say this. If I could get a script for Vascepa my current co-pay, because I’m in stage 4 for Part D drug cost, would be only $45 and change for 90 days (5% of total Silverscript plan price). If I wait till January, starting a new Part D year, I’ll be on stage 2 (my plan has no deductible) and my cost will be maybe $150-180 for 90 days.